ArgusEye, a Swedish deep tech company developing advanced sensor solutions for real-time monitoring of biological systems and processes, has been awarded €6.25 million in blended funding from the European Innovation Council (EIC) Accelerator — one of Europe’s most competitive and prestigious funding programmes for breakthrough startups and SMEs.
The Linköping-based company was selected as one of just 61 companies across Europe in this highly competitive round. The package includes a €2.5 million grant alongside the option of up to €3.75 million in additional equity investment.
The problem with biomanufacturing today
Pharmaceutical and biotech manufacturers face a persistent challenge: biological processes are complex, variable, and difficult to monitor in real time. Without accurate, continuous visibility into what is happening inside a bioreactor or production system, manufacturers must rely on offline sampling — a slow, costly, and error-prone approach that creates bottlenecks at every stage of drug development and production.
ArgusEye’s answer is the Auga™ platform, a sensor-driven system that delivers real-time insights and intelligent process control directly within biological manufacturing environments. By embedding continuous monitoring at the point of production, the platform gives scientists and engineers the data they need to intervene faster, reduce waste, and improve both the safety and consistency of biological medicines.
Scaling a platform with global ambitions
The EIC funding will be deployed across three areas: accelerating development of the Auga™ platform, expanding ArgusEye’s international presence, and scaling operations to meet what the company describes as rapidly growing global demand.
The timing reflects a broader shift in how the pharmaceutical industry thinks about bioprocess intelligence. As biologics — including cell and gene therapies, monoclonal antibodies, and biosimilars — become an increasingly dominant share of the drug pipeline, the tools used to manufacture them are coming under sharper scrutiny. Regulators and manufacturers alike are pushing toward greater process understanding and real-time release testing, trends that play directly to ArgusEye’s strengths.
Dr. Erik Martinsson, CEO and Co-founder of ArgusEye, described the award as a defining milestone for the company. “Our vision has always been to make biomanufacturing smarter, safer, and more efficient. This support will allow us to accelerate the development of the Auga™ platform and bring its benefits to more customers and partners around the world even faster.”
A vote of confidence from Europe’s top innovation funder
Being selected among just 61 companies continent-wide underscores the strength of ArgusEye’s technology and commercial case. The EIC Accelerator is specifically designed for innovations with the potential to create new markets or transform existing ones — and biomanufacturing process intelligence is increasingly seen as exactly that kind of opportunity, as the global biologics market continues its rapid expansion.
For Linköping — already home to a strong cluster of medtech and life science activity anchored in part by Linköping University — ArgusEye’s recognition adds another high-profile data point to the city’s growing reputation as a hub for deep tech innovation in Sweden.
Fast facts:
- Stage: EIC Accelerator (Horizon Europe)
- Amount awarded: €6.25M total (€2.5M grant + up to €3.75M equity option)
- HQ: Linköping, Sweden
- Core product: Auga™ sensor platform for biomanufacturing
- Focus: Real-time monitoring of biological systems and processes
